
## Tatsuhiro Terada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2769941/publications.pdf Version: 2024-02-01



ΤΑΤΩΙΙΗΙΡΟ ΤΕΡΑΠΑ

#	Article	IF	CITATIONS
1	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease. European Journal of Neurology, 2022, 29, 1324-1334.	3.3	8
2	Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. Neurology, 2021, 96, e81-e92.	1.1	31
3	tDCS-induced modulation of GABA concentration and dopamine release in the human brain: A combination study of magnetic resonance spectroscopy and positron emission tomography. Brain Stimulation, 2021, 14, 154-160.	1.6	30
4	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. Molecular Neurodegeneration, 2021, 16, 28.	10.8	32
5	In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease. Neurology, 2020, 94, e1592-e1604.	1.1	70
6	Coexistence of cerebral hypometabolism and neuroinflammation in the thalamo-limbic-brainstem region in young women with functional somatic syndrome. EJNMMI Research, 2020, 10, 29.	2.5	1
7	Alterations in serotonin transporter and body image-related cognition in anorexia nervosa. NeuroImage: Clinical, 2019, 23, 101928.	2.7	11
8	In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease. Journal of Neurology, 2019, 266, 2186-2196.	3.6	44
9	Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 529-538.	2.6	4
10	In vivo Depiction of α7 Nicotinic Receptor Loss for Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 61, 1355-1365.	2.6	22
11	Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study. Journal of the Neurological Sciences, 2018, 385, 30-33.	0.6	10
12	Reduced gray matter volume is correlated with frontal cognitive and behavioral impairments in Parkinson's disease. Journal of the Neurological Sciences, 2018, 390, 231-238.	0.6	11
13	Depiction of microglial activation in aging and dementia: Positron emission tomography with [ <sup>11</sup> C]DPA713 versus [ <sup>11</sup> C]( <i>R</i> )PK11195. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 877-889.	4.3	62
14	Frontal assessment battery and frontal atrophy in amyotrophic lateral sclerosis. Brain and Behavior, 2017, 7, e00707.	2.2	15
15	Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study. Annals of Nuclear Medicine, 2016, 30, 579-587.	2.2	97
16	Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 817-830.	2.6	6
17	Correlation of frontal atrophy with behavioral changes in amyotrophic lateral sclerosis. Neurology and Clinical Neuroscience, 2016, 4, 85-92.	0.4	6
18	The Possible Link between GABAergic Dysfunction and Cognitive Decline in a Patient with Idiopathic Hypoparathyroidism. Internal Medicine, 2015, 54, 2245-2250.	0.7	3

TATSUHIRO TERADA

#	Article	IF	CITATIONS
19	An altered GABA-A receptor function in spinocerebellar ataxia type 6 and familial hemiplegic migraine type 1 associated with the CACNA1A gene mutation. BBA Clinical, 2014, 2, 56-61.	4.1	13
20	SPG3A-linked hereditary spastic paraplegia associated with cerebral glucose hypometabolism. Annals of Nuclear Medicine, 2013, 27, 303-308.	2.2	10
21	Altered GABAergic system in the living brain of a patient with spinocerebellar ataxia type 8. Journal of Neurology, 2013, 260, 3164-3166.	3.6	2
22	Frontal lobe-mediated behavioral changes in amyotrophic lateral sclerosis: Are they independent of physical disabilities?. Journal of the Neurological Sciences, 2011, 309, 136-140.	0.6	29